The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CLNN | +96.85% | -94.24% | -43.46% | -95% |
| S&P | +19.89% | +109.18% | +15.89% | +136% |
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.03M | -70.3% |
| Gross Profit | -$0.34M | 0.6% |
| Gross Margin | -1255.56% | -880.8% |
| Market Cap | $35.12M | -23.2% |
| Market Cap / Employee | $0.46M | 0.0% |
| Employees | 76 | -10.6% |
| Net Income | -$7.42M | -9.3% |
| EBITDA | -$5.50M | 21.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.29M | -66.4% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0.1 | 113.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $19.46M | 68.6% |
| Short Term Debt | $1.39M | -93.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -95.12% | -38.8% |
| Return On Invested Capital | -229.33% | -29.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.73M | 25.7% |
| Operating Free Cash Flow | -$4.73M | 25.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1170.92 | -176.53 | -2.81 | -6.82 | -163.52% |
| Price to Sales | 1429.95 | 125.60 | 77.66 | 130.20 | 25.76% |
| Price to Tangible Book Value | -1171.84 | -176.54 | -2.81 | -6.82 | -103.18% |
| Enterprise Value to EBITDA | -82.37 | -6.26 | -10.43 | -9.24 | 13.70% |
| Return on Equity | -3702.2% | -289.7% | -416.9% | -1738.4% | 191.93% |
| Total Debt | $22.88M | $20.84M | $20.94M | $20.85M | -36.09% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
